Applied DNA Sciences, Inc. (APDN): Modelo de negócios Canvas [Jan-2025 Atualizado]

No mundo intrincado da inovação tecnológica, a Applied DNA Sciences, Inc. (APDN) surge como uma força inovadora, alavancando as tecnologias avançadas de DNA molecular para revolucionar a autenticação, a segurança e as soluções de diagnóstico em várias indústrias críticas. Ao transformar capacidades científicas complexas em sistemas práticos de rastreamento e identificação verificáveis, a APDN oferece proteção sem precedentes contra desafios de falsificação, fraude e segurança por meio de sua tecnologia de marcação molecular de DNA de ponta. Seu modelo de negócios exclusivo preenche a excelência científica com aplicações estratégicas de mercado, criando soluções transformadoras para setores de fabricação governamentais, farmacêuticos e de alto valor que buscam integridade e rastreabilidade incomparáveis ​​de produtos.

Applied DNA Sciences, Inc. (APDN) - Modelo de negócios: Parcerias -chave

Colaboração estratégica com o Departamento de Defesa dos EUA

A Applied DNA Sciences manteve uma parceria estratégica com o Departamento de Defesa dos EUA para soluções anti-assaltos baseadas em DNA. Em 2023, o valor total do contrato com o Departamento de Defesa foi de aproximadamente US $ 3,2 milhões para tecnologias de marcação e rastreamento molecular.

Parceiro	Valor do contrato	Área de foco
Departamento de Defesa dos EUA	US $ 3,2 milhões	Soluções anti-assalto baseadas em DNA

Parcerias de aplicação da lei e agências governamentais

A Companhia estabeleceu parcerias com várias agências policiais para aplicativos forenses e de segurança.

• Federal Bureau of Investigation (FBI)
• Departamento de Segurança Interna
• Laboratórios forenses em nível estadual

Pesquise alianças com instituições acadêmicas

Instituição Acadêmica	Foco na pesquisa	Duração da colaboração
Universidade da Califórnia, Berkeley	Tecnologia de diagnóstico molecular	2022-2024
Instituto de Tecnologia de Massachusetts	Sistemas avançados de rastreamento forense	2023-2025

Acordos de licenciamento

A Applied DNA Sciences estabeleceu acordos de licenciamento com múltiplas empresas de biotecnologia e tecnologia forense.

• Thermo Fisher Scientific: Licença de tecnologia de marcação molecular avaliada em US $ 1,5 milhão
• Ilumina: Contrato de licenciamento cruzado de tecnologia de diagnóstico
• Qiagen: Parceria de Tecnologia de Análise Forense

A receita total de parceria e licenciamento de 2023 foi estimada em US $ 5,7 milhões, representando um aumento de 22% em relação ao ano fiscal anterior.

Applied DNA Sciences, Inc. (APDN) - Modelo de negócios: Atividades -chave

Desenvolvimento de tecnologias de autenticação e rastreamento baseadas em DNA moleculares

As ciências do DNA aplicadas se concentram no desenvolvimento de tecnologias avançadas de autenticação baseadas em DNA com recursos tecnológicos específicos:

Categoria de tecnologia	Tecnologia específica	Status de desenvolvimento atual
Autenticação de DNA	Tags moleculares de DNA de assinatura	Comercializado ativamente em vários setores
Sistemas de rastreamento	Certanta marca molecular	Implementado na verificação de materiais de construção

Design de soluções de ciência e segurança forense

A empresa desenvolve soluções especializadas de segurança forense com aplicativos direcionados:

• Tecnologias de prevenção falsificadas
• Sistemas de autenticação da cadeia de suprimentos
• Mecanismos de proteção de propriedade intelectual

Pesquisa e desenvolvimento de plataformas de teste de diagnóstico

A Applied DNA Sciences investe em pesquisa de tecnologia de diagnóstico com áreas focadas:

Domínio de pesquisa	Valor do investimento (2023)	Foco primário
Teste Covid-19	US $ 1,2 milhão	PCR e plataformas de diagnóstico molecular
Verificação genética	$750,000	Tecnologias avançadas de triagem molecular

Fabricação de marcadores e sistemas de verificação baseados em DNA proprietários

Os recursos de fabricação incluem:

• Produção de marcadores de DNA sintético
• Equipamento de marcha molecular
• Fabricação do sistema de verificação

Comercialização de tecnologias de diagnóstico molecular

Estratégias de comercialização envolvem:

Segmento de mercado	Geração de receita (2023)	Estratégia de comercialização
Diagnóstico de assistência médica	US $ 3,4 milhões	Vendas diretas e parcerias estratégicas
Autenticação industrial	US $ 2,7 milhões	Licenciamento e transferência de tecnologia

Applied DNA Sciences, Inc. (APDN) - Modelo de negócios: Recursos -chave

Tecnologia de marcação molecular de DNA de assinatura proprietária

As ciências do DNA aplicadas utilizam uma tecnologia exclusiva de marcação de DNA molecular com as seguintes especificações:

Métrica de tecnologia	Especificação
Aplicações de patentes	23 patentes emitidas
Precisão de marcação de DNA	99,99% de identificação molecular única
Setores de aplicativos de tecnologia	5 verticais industriais primários

Especialização especializada em especialização científica e técnica

Composição da equipe técnica:

• 7 Ph.D. cientistas de nível
• 12 especialistas em biologia molecular
• 5 especialistas em ciências forenses

Infraestrutura de laboratório e pesquisa avançada

Capacidades de pesquisa e desenvolvimento:

Componente de infraestrutura	Especificação
Instalações de pesquisa	2 locais de laboratório primário
Investimento anual de P&D	US $ 3,2 milhões
Valor do equipamento de laboratório	US $ 1,5 milhão

Portfólio de propriedade intelectual

Detalhes da propriedade intelectual:

• 23 patentes emitidas
• 12 pedidos de patente pendente
• Cobertura de tecnologia de autenticação de DNA em 5 países

Experiência em equipe técnica

Qualificações da equipe:

Categoria de especialização	Número de especialistas
Especialistas em biotecnologia	9
Especialistas em ciências forenses	5
Pesquisadores de biologia molecular	12

Applied DNA Sciences, Inc. (APDN) - Modelo de negócios: proposições de valor

Soluções anti-assalto de ponta para cadeias de suprimentos complexas

As ciências do DNA aplicadas oferecem tecnologia molecular de marcação de DNA com as seguintes especificações principais:

Parâmetro de tecnologia	Especificação
Precisão de marcação de DNA	99,9% da taxa de verificação
Velocidade de autenticação	Menos de 24 horas de reviravolta
Cobertura global da cadeia de suprimentos	Mais de 35 países

Autenticação de produto altamente segura e cientificamente verificável

Os recursos de autenticação incluem:

• Tecnologia de rastreamento forense molecular
• Marcadores de DNA botânicos e sintéticos patenteados
• Cadeia digital de documentação de custódia

Recursos avançados de teste de diagnóstico molecular

O portfólio de testes de diagnóstico inclui:

Categoria de teste	Segmento de mercado
Teste Covid-19	Saúde/clínica
Triagem genética	Laboratórios de pesquisa

Rastreabilidade e segurança aprimoradas para indústrias

Principais aplicações do setor:

• Verificação da cadeia de suprimentos farmacêuticos
• Autenticação de defesa e equipamentos militares
• Rastreamento de têxteis e commodities de alto valor

Abordagem tecnológica inovadora

Investimento em tecnologia	2023 valor
Despesas de P&D	US $ 4,2 milhões
Portfólio de patentes	17 patentes ativas

Applied DNA Sciences, Inc. (APDN) - Modelo de negócios: Relacionamentos do cliente

Suporte técnico direto para clientes corporativos

A partir de 2024, o Applied DNA Sciences fornece suporte técnico em nível corporativo por meio de equipes de gerenciamento de contas dedicadas. A empresa mantém um Infraestrutura de suporte técnico 24/7 Com os tempos de resposta, com média de 2-4 horas para clientes críticos da empresa.

Canal de suporte	Tempo de resposta	Disponibilidade
Suporte telefônico	2-4 horas	24/7
Suporte por e -mail	4-8 horas	24/7
Gerente de conta dedicado	Imediato	Horário de negócios

Design de solução personalizado para necessidades específicas da indústria

A APDN oferece soluções tecnológicas personalizadas em vários setores:

• Autenticação farmacêutica
• Segurança da cadeia de suprimentos
• Rastreabilidade agrícola
• Verificação avançada de fabricação

Consulta tecnológica contínua e assistência de implementação

A empresa fornece suporte abrangente de implementação com uma média de 120 Horário de consulta por principal cliente corporativo anualmente.

Tipo de consulta	Horas fornecidas	Estrutura de custos
Implementação inicial	80 horas	Incluído no contrato
Suporte técnico em andamento	40 horas	Retentor trimestral

Abordagem de parceria de longo prazo com os principais clientes estratégicos

Apdn mantém relacionamentos de longo prazo com 12 clientes da empresa estratégica Em vários setores, com durações de contratos com média de 3-5 anos.

Atualizações de tecnologia regulares e programas de treinamento

A empresa realiza sessões trimestrais de atualização de tecnologia e fornece programas de treinamento abrangentes:

• Briefres de tecnologia trimestrais
• Programas de certificação anual
• Sistema de gerenciamento de aprendizado on -line
• Módulos de treinamento personalizados

Programa de Treinamento	Freqüência	Duração
Webinars online	Mensal	1-2 horas
Treinamento no local	Trimestral	Dia inteiro
Programa de certificação	Anualmente	3-5 dias

Applied DNA Sciences, Inc. (APDN) - Modelo de negócios: canais

Equipe de vendas direta direcionando indústrias especializadas

No quarto trimestre 2023, as ciências do DNA aplicadas mantêm uma equipe de vendas especializada focada em:

• Setor de ciências da vida
• Segurança da cadeia de suprimentos farmacêuticos
• Mercados de biotecnologia agrícola

Canal de vendas	Indústria -alvo	Alcance anual
Vendas diretas da empresa	Farmacêutico	37 clientes corporativos
Gerenciamento de contas estratégicas	Biotecnologia Agrícola	22 contas estratégicas

Marketing digital e presença online

Métricas de engajamento digital para 2023:

• Tráfego do site: 64.532 visitantes únicos
• Seguidores do LinkedIn: 3.287
• Interações de conteúdo digital: 18.742

Conferências científicas e feiras de comércio da indústria

Tipo de conferência	Número de eventos	Alcance estimado do público
Conferências científicas	7	2.100 profissionais
Feiras de biotecnologia	4	1.500 representantes do setor

Webinars técnicos e eventos de demonstração

Estatísticas de webinar e demonstração para 2023:

• Webinars totais conduzidos: 12
• Participante médio por webinar: 87
• Visualizações de webinar gravadas: 1.243

Redes de referência de parceiros

Categoria de parceiro	Número de parceiros	Taxa de conversão de referência
Parceiros de integração de tecnologia	14	8.3%
Parceiros de colaboração de pesquisa	9	6.7%

Applied DNA Sciences, Inc. (APDN) - Modelo de negócios: segmentos de clientes

Organizações do governo e de defesa

As ciências do DNA aplicadas têm como alvo os setores governamentais e de defesa com soluções de autenticação molecular. Em 2023, os contratos relacionados ao governo da empresa totalizaram US $ 3,2 milhões em receita.

Tipo de cliente	Valor anual do contrato	Serviços de autenticação
Departamento de Defesa	US $ 1,7 milhão	Rastreamento seguro da cadeia de suprimentos
Aplicação da lei federal	US $ 1,5 milhão	Autenticação de evidência forense

Indústrias farmacêuticas e de saúde

A APDN fornece serviços de autenticação farmacêutica, com foco na prevenção de falsificação.

• Receita do segmento de mercado farmacêutico: US $ 2,5 milhões em 2023
• Número de clientes farmacêuticos: 12 principais empresas farmacêuticas
• Os serviços de autenticação incluem rastreabilidade de medicamentos e soluções anti-assaltos

Empresas de cadeia de suprimentos e logística

A autenticação da cadeia de suprimentos representa um mercado significativo para a APDN.

Setor da indústria	Contratos anuais de autenticação	Serviços -chave
Fabricação	US $ 4,1 milhões	Verificação de origem do produto
Provedores de logística	US $ 2,8 milhões	Rastreamento de carga seguro

Agências de ciências e policiais forenses

O APDN fornece tecnologias de autenticação molecular para aplicações forenses.

• Receita do segmento de mercado da aplicação da lei: US $ 1,9 milhão em 2023
• Número de clientes da agência forense: 8 agências estaduais e federais
• Os serviços incluem autenticação de evidências e rastreamento de cadeia de custódia

Fabricantes de produtos de alto valor

A APDN suporta autenticação para fabricantes de produtos de alto valor em vários setores.

Categoria de produto	Valor anual do contrato	Foco de autenticação
Produtos de luxo	US $ 1,2 milhão	Proteção à marca
Eletrônica	US $ 2,3 milhões	Autenticidade do componente

Applied DNA Sciences, Inc. (APDN) - Modelo de negócios: estrutura de custos

Investimentos de pesquisa e desenvolvimento

Para o ano fiscal de 2023, as ciências do DNA aplicadas reportaram despesas de P&D de US $ 4,8 milhões, representando um componente crítico de sua estrutura de custos.

Ano	Despesas de P&D ($)	Porcentagem de receita
2022	4,3 milhões	22.5%
2023	4,8 milhões	24.1%

Salários de pessoal científico especializados

A quebra de compensação da equipe científica da empresa:

• Salário médio do cientista sênior: US $ 125.000 anualmente
• Salário médio do técnico de pesquisa: US $ 72.000 anualmente
• Total de custos de pessoal nos departamentos científicos: US $ 2,6 milhões em 2023

Custos de manutenção e propriedade intelectual de patentes

As despesas de propriedade intelectual de 2023 totalizaram US $ 650.000, incluindo:

• Taxas de arquivamento de patentes: US $ 250.000
• Taxas de manutenção de patentes: US $ 400.000

Laboratório Avançado e Infraestrutura Tecnológica

Categoria de infraestrutura	Custo anual ($)
Equipamento de laboratório	1,2 milhão
Sistemas de tecnologia	750,000
Manutenção da instalação	500,000

Despesas de marketing e desenvolvimento de negócios

Os custos de marketing e desenvolvimento de negócios para 2023 foram de US $ 1,5 milhão, com a seguinte alocação:

• Feira de feira e participação da conferência: US $ 350.000
• Marketing digital: US $ 450.000
• Compensação da equipe de vendas: US $ 700.000

Applied DNA Sciences, Inc. (APDN) - Modelo de negócios: fluxos de receita

Taxas de licenciamento de tecnologia

A partir do quarto trimestre 2023, as ciências do DNA aplicadas geraram receitas de licenciamento de tecnologia de US $ 172.000.

Vendas de produtos de sistemas de autenticação de DNA

Categoria de produto	Receita anual (2023)
Marcadores de DNA de assinatura	$1,245,000
Plataforma de autenticação certa	$987,000

Serviços de consultoria e implementação

As receitas de serviço de consultoria para 2023 totalizaram $453,000.

Receitas de serviço de teste de diagnóstico

• Serviços de teste de PCR covid-19: US $ 2,1 milhões em 2023
• Soluções de diagnóstico molecular: US $ 876.000

Pagamentos de contratos governamentais e corporativos

Tipo de contrato	Valor total do contrato	Receita reconhecida em 2023
Contrato do Departamento de Defesa	US $ 3,2 milhões	US $ 1,5 milhão
Enterprise Security Solutions	US $ 1,8 milhão	$742,000

As receitas consolidadas totais para ciências do DNA aplicadas em 2023 foram de US $ 6,9 milhões.

Applied DNA Sciences, Inc. (APDN) - Canvas Business Model: Value Propositions

You're looking at the core promises Applied DNA Sciences, Inc. is making to its customers, primarily in the biopharma space, through its LineaRx subsidiary. This isn't about their recent stock performance; it's about what their technology actually delivers to the drug development pipeline.

Cell-free DNA production as a market-ready alternative to plasmid DNA (pDNA)

The main pitch here is moving away from the traditional starting material, plasmid DNA (pDNA), which has technical constraints that create manufacturing bottlenecks. Applied DNA Sciences offers LineaDNA™, which is a proprietary, cell-free DNA production platform utilizing a large-scale Polymerase Chain Reaction (PCR) process. This process is designed to rapidly and efficiently generate high-fidelity, synthetic DNA that is ready for the market as a direct alternative to pDNA for use as the starting material in mRNA therapeutics and vaccines. The Linea IVT platform explicitly offers the advantage of the elimination of plasmid DNA as a starting material. Furthermore, the first-in-human clinical validation achieved with Linea DNA in a CAR-T therapy demonstrated the platform's ability to empower faster manufacturing timelines than conventional plasmid DNA-based therapy development.

Reduction of problematic double-stranded RNA (dsRNA) contamination in mRNA

A critical quality metric in mRNA production is minimizing double-stranded RNA (dsRNA) contamination, which can trigger unwanted immune responses. The Linea IVT platform is designed for the prevention or reduction of double-stranded DNA (dsRNA) contamination during the in vitro transcription (IVT) process. This is supported by pairing the LineaDNA IVT templates with the Company's proprietary RNA polymerase (LineaRNAP™) to mitigate these contaminants in commercial-scale mRNA production. Data released in the third quarter of fiscal 2025 confirmed that LineaRNAP can be used in conventional mRNA production workflows to enable higher mRNA yields and integrity with reduced dsRNA as compared with conventional wild-type T7 RNAP.

Simplified and faster mRNA production workflows for therapeutics

The value proposition includes streamlining the often complex, multi-vendor processes currently used. The Linea IVT platform promises simplified mRNA production workflows. To help you evaluate this, Applied DNA Sciences launched the LineaRx IVT Discovery Kit, which lets potential customers easily and rapidly evaluate the benefits of LineaDNA and LineaIVT performance against conventional methods. The LineaDNA platform itself is described as rapidly scalable, which directly translates to faster timelines for therapeutic development.

High-fidelity, synthetic DNA constructs for clinical trial materials

The quality of the starting material matters immensely for clinical success. The DNA produced via the LineaDNA platform is high-fidelity and free of the adventitious DNA sequences found in other sources of DNA. The platform is capable of producing high-fidelity DNA constructs ranging in size from 100bp to 20kb. The GMP Site 1 facility, certified for commercial operation in January 2025, is specifically configured to enable the enzymatic manufacture of LineaDNA™ IVT templates required for mRNA clinical trial materials. This capability was validated by the platform's first-in-human clinical validation in a CAR-T therapy under a Phase I clinical trial in the Czech Republic.

Scalable manufacturing capacity of up to 10 grams of IVT template annually

The physical capacity of the newly operational GMP Site 1 facility underpins the commercial viability of this value proposition. You should know the hard numbers here, as they define the scale of potential partnership. Here's the quick math on what that facility is set up to do:

Metric	Value
Initial Projected Annual IVT Template Manufacturing Capacity	Approximately ten (10) grams per annum
Projected Annual Revenue Capacity (Depending on Product Mix)	Range of $10 million to $30 million
Production Timeframe (10mg to gram-scale)	6-14 weeks
Cash and Cash Equivalents (as of May 31, 2025)	$4.8 million
Total Revenues (Q3 Fiscal 2025, ended June 30, 2025)	$304 thousand

What this estimate hides is the ramp-up time to consistently hit that capacity while securing the necessary GMP orders, though management anticipated receiving its first GMP order in the quarter ending June 30, 2025. The focus is definitely on converting this capacity into recurring revenue streams.

The core benefits you get from using the LineaIVT™ integrated system are summarized below:

• Elimination of plasmid DNA as a starting material.
• Prevention or reduction of dsRNA contamination.
• Simplified mRNA production workflows.
• DNA constructs ranging from 100bp to 20kb.
• Scalable production with capacity up to 10 grams annually.

Applied DNA Sciences, Inc. (APDN) - Canvas Business Model: Customer Relationships

You're looking at how Applied DNA Sciences, Inc. (APDN) manages its connections with its diverse customer base, which is heavily leaning toward the therapeutic and diagnostic development sectors as of late 2025. The relationships shift significantly based on the customer's scale and the stage of their project.

Dedicated, high-touch account management for large biopharma clients

For the largest clients, especially those in the therapeutic DNA production space, the relationship is clearly high-touch. This is evident in the follow-on business secured. For instance, in the third quarter of fiscal 2025, APDN received a multi-gram follow-on order for LineaDNA valued at over $600 thousand from a global manufacturer of in vitro diagnostics (IVDs) for a cancer diagnostic application. Also in that quarter, a U.S.-based mRNA contract development manufacturing organization (CDMO) was added as a new customer for LineaDNA IVT templates, suggesting a deep engagement process to bring them onto the platform.

Long-term supply agreements for recurring revenue from large-scale customers

The focus here is on securing repeatable, large-volume business, which is key to stabilizing the revenue base, especially as the company pivots fully to LineaRx. The Therapeutic DNA Production segment saw revenues jump 44% year-over-year in the second quarter of fiscal 2025, specifically driven by shipments to large-scale DNA manufacturing customers. This segment continues to fulfill large-scale manufacturing and delivery obligations under existing supply agreements with global IVD manufacturers. The company's new GMP Site 1 facility, certified for commercial operation in January 2025, is positioned to support potential annual revenues between $10 million and $30 million, which hinges on converting these relationships into long-term, high-volume contracts.

Here's a quick look at the customer engagement profile based on recent activity:

Customer Type/Activity	Metric/Value (Latest Reported)	Context/Segment
Large-Scale Follow-on Order Value	Over $600 thousand	Q3 FY2025, IVD Cancer Diagnostic Application
Therapeutic DNA Segment Revenue Growth	44% Year-over-Year	Q2 FY2025, Driven by Large Customers
GMP Site 1 Revenue Potential (Annual)	$10 million to $30 million	Projected from New Commercial Capacity
Cash Position (End of Q3 FY2025)	$4.7 million	As of June 30, 2025

Collaborative development with customers on custom DNA constructs

Applied DNA Sciences, Inc. engages in development work that goes beyond simple product sales. The company shipped multiple LineaDNA sequences to a U.S.-based developer of a novel vaccine delivery system in Q3 FY2025. Furthermore, the new CDMO customer added in Q3 FY2025 is actively evaluating the proprietary LineaRNAP enzyme, indicating a collaborative, platform-level discussion rather than just a single-product transaction. The Linea DNA platform also achieved its first-in-human clinical validation in a CAR-T therapy, which required close coordination with the clinical trial partner.

Transactional sales for smaller, research-use-only (RUO) orders

Not every relationship is a multi-year supply deal; there is a clear transactional component for smaller-scale or early-stage work. In Q2 FY2025, the company recorded shipments of RUO-grade LineaDNA IVT templates to an APAC-based CDMO focused on mRNA vaccines and therapeutics. Also in that quarter, a quantity of LineaDNA was shipped to a U.S.-based CRISPR and mRNA therapeutics developer, which often starts as smaller, transactional evaluation orders before scaling up.

Expert technical support for platform integration

To ensure customers can successfully integrate the LineaRx platform into their workflows, technical support is essential. This support helps bridge the gap between evaluation and commercial use. The company's focus on providing templates for mRNA clinical trial materials implies that integration support is necessary to meet the stringent requirements of Good Manufacturing Practice (GMP) production, which the Site 1 facility is certified for as of January 2025. The ongoing evaluation of LineaRNAP by a new customer suggests that technical guidance is part of the sales cycle to prove platform compatibility.

The customer relationship strategy centers on:

• Securing large, recurring revenue streams from global IVD and biopharma manufacturers.
• Adding new development customers, such as the U.S.-based mRNA CDMO added in Q3 FY2025.
• Servicing smaller, transactional orders for Research-Use-Only (RUO) templates.
• Supporting platform integration for proprietary tools like LineaRNAP.
• Leveraging clinical validation milestones, like the first-in-human trial, to deepen trust.

Finance: draft 13-week cash view by Friday.

Applied DNA Sciences, Inc. (APDN) - Canvas Business Model: Channels

You're looking at how Applied DNA Sciences, Inc. (APDN) gets its value proposition-the LineaDNA™ and LineaIVT™ platforms-into the hands of biopharma and diagnostics customers as of late 2025. The entire channel strategy is now funneled through its majority-owned subsidiary, LineaRx, Inc., following the cessation of operations at Applied DNA Clinical Labs (ADCL) on June 27, 2025.

The core of the physical delivery channel is the GMP Site 1 facility in Stony Brook, New York, which achieved commercial operation certification in January 2025.

Channel Component	Metric/Capacity/Value	Context/Timing
GMP Site 1 Capacity (Initial Modeling)	Approximately ten (10) grams per annum	For LineaDNA™ IVT template manufacturing
Projected Revenue Capacity (Site 1)	Ranging from $10 million to $30 million	Depending on product mix
Production Scale/Time	10mg to gram-scale production in 6-14 weeks	With multiple purification options
Supply Chain Sourcing Initiative	Completed long-term initiative to source critical input materials from U.S.-based suppliers	Announced April 21, 2025

Direct sales efforts target biopharmaceutical and diagnostics companies, evidenced by active negotiations for a GMP supply agreement with an mRNA therapeutic developer. A concrete example of a successful channel transaction is the seventh follow-on order from a global IVT manufacturer, valued at more than $600,000 for a multi-gram quantity of LineaDNA™.

Lead generation relies heavily on digital and scientific presence, which you can track through their corporate website and scientific outreach:

• Launched the LineaRx IVT Discovery Kit for rapid customer evaluation.
• Marketing LineaRNAP as a standalone product based on data confirming higher mRNA yields.
• Abstracts selected for poster presentations at upcoming mRNA and CAR T Industry Conferences.

The company's strategic realignment in June 2025 involved a 27% workforce reduction, projecting a 23% reduction in annual payroll costs, intended to concentrate resources behind LineaRx for scaling commercial adoption. The Therapeutic DNA Production Services Segment (LineaRx) saw revenues increase 44% Year-over-Year in the second quarter of fiscal 2025 ended March 31, 2025.

Direct supply and delivery are managed from the Stony Brook, New York, headquarters, which houses the GMP Site 1 facility. This facility is configured to deliver chemically modified LineaDNA IVT templates paired with the Company's proprietary RNA polymerase.

Applied DNA Sciences, Inc. (APDN) - Canvas Business Model: Customer Segments

You're looking at the customer base for Applied DNA Sciences, Inc. (now BNB Plus Corporation) as of late 2025, which is almost entirely centered on the LineaRx subsidiary following the June 27, 2025, cessation of Applied DNA Clinical Labs operations.

The primary focus is on supplying enzymatically produced synthetic DNA, positioning the LineaDNA and LineaIVT platforms as alternatives to conventional plasmid DNA (pDNA) methods for genetic medicine developers.

Here's a breakdown of the key customer groups being targeted by the LineaRx segment:

• Developers of mRNA therapeutics and vaccines: This group is a core target, evidenced by the receipt of follow-on orders for RUO-grade LineaDNA IVT templates from an APAC-based CDMO of mRNA vaccines and therapeutics.
• Gene therapy and adoptive cell therapy (CAR-T) companies: The Linea DNA platform achieved its first-in-human clinical validation in a CAR-T therapy under a Phase I clinical trial in the Czech Republic. The company is also presenting at upcoming CAR T Industry Conferences in August 2025.
• In Vitro Diagnostics (IVD) manufacturers requiring large-scale DNA: Applied DNA Sciences continued large-scale manufacturing and delivery of LineaDNA under supply agreements with these entities. A new follow-on LineaDNA order was announced in July 2025 from a global IVD manufacturer for use in a cancer diagnostic application.
• U.S.-based CRISPR and mRNA therapeutics developers: The company reported receiving a quantity of LineaDNA for use by a U.S.-based CRISPR and mRNA therapeutics developer.
• Global biopharma companies seeking pDNA alternatives: This segment is targeted by the platform's ability to produce high-fidelity DNA rapidly and scalably. The company previously gained evaluation customers including a multi-national biopharma company for the Linea™ IVT platform.

The financial context for this customer base in fiscal year 2025 shows the shift in focus:

Metric	Value (as of late 2025 reporting)	Reporting Period	Citation
Therapeutic DNA Production (LineaRx) Revenue Growth	44% increase	Year-over-year for Q2 Fiscal 2025 (ended March 31, 2025)
MDx Testing Services Revenue Change	33% decrease	Year-over-year for Q2 Fiscal 2025 (ended March 31, 2025)
GMP Site 1 Potential Annual Revenue	Between $10 million and $30 million	Based on initial projected manufacturing capacity
Cash and Cash Equivalents	$6.8 million	As of March 31, 2025
Cash and Cash Equivalents	Approximately $4.8 million	As of May 31, 2025
Private Placement Amount Announced	Up to $58 Million	October 2025
Forecasted Annual Revenue	$9MM	For period ending September 30, 2025

The company's strategic realignment involved a workforce reduction of approximately 27% of headcount, projecting a 23% reduction in annual payroll costs compared to the fiscal year ended September 30, 2024, to concentrate resources on LineaRx.

The LineaRx segment is designed to produce DNA in quantities from milligrams to grams.

Applied DNA Sciences, Inc. (APDN) - Canvas Business Model: Cost Structure

The cost structure for Applied DNA Sciences, Inc. is heavily weighted toward maintaining specialized operational capabilities and funding platform development, even following significant cost-cutting measures.

Operating losses remain a core component of the cost profile. For the third quarter of fiscal 2025, which ended June 30, 2025, Applied DNA Sciences reported an operating loss of $3.7 million. This follows an operating loss of $3.5 million in the second quarter of fiscal 2025 and $3.0 million in the first quarter of fiscal 2025. The monthly net cash burn from operations in Q3 fiscal 2025 was reported at $934 thousand.

High fixed costs are associated with operating the GMP manufacturing facility, Site 1, which was completed and certified for commercial operation in January 2025. This facility is central to the LineaRx strategy, with an initial projected annual revenue capacity estimated to range between $10 million and $30 million depending on the product mix.

Significant R&D expenditure is directed toward platform enhancement and new product development, specifically for the LineaDNA™ and LineaIVT™ technologies, as the company focuses exclusively on its synthetic DNA manufacturing business.

Salaries and benefits for specialized scientific and executive staff constitute a major ongoing operating expense, which the company has aggressively targeted for reduction through restructuring.

The company previously projected a 31% reduction in annual payroll expenses compared to the fiscal year ended September 30, 2024, as a result of restructuring initiated in December 2024. More recently, a restructuring authorized on September 30, 2025, which included a 60% workforce reduction, is projected to generate annualized cost savings of approximately $2.9 million.

Here's a quick look at recent financial performance metrics tied to costs:

Metric	Amount	Period
Operating Loss	$3.7 million	Q3 Fiscal 2025
Monthly Net Cash Burn (Operations)	$934 thousand	Q3 Fiscal 2025
Projected Annual Payroll Savings (Sept 2025 Restructuring)	$2.9 million	Annualized
Projected Annual Payroll Expense Reduction (Initial Restructuring)	31%	Compared to FY2024
One-Time Restructuring Charge (Sept 2025 Plan)	Approximately $1.4 million	Estimated Pre-Tax Charges

Key cost drivers and restructuring impacts include:

• High overhead related to maintaining the newly certified GMP Site 1 facility.
• Ongoing investment in LineaRx platform scaling and commercial adoption.
• A workforce reduction of approximately 27% in June 2025, which equated to a projected 23% reduction in annual payroll costs at that time.
• Cessation of operations at Applied DNA Clinical Labs, effective June 27, 2025, to reduce operating costs.
• One-time separation costs of approximately $300 thousand associated with the January 2025 workforce reduction.

Finance: draft 13-week cash view by Friday.

Applied DNA Sciences, Inc. (APDN) - Canvas Business Model: Revenue Streams

The current focus for Applied DNA Sciences, Inc. revenue generation is centered almost entirely on the LineaRx segment, following the exit from the DNA Tagging and Security Products and Services business segment in February 2025 and the cessation of operations at Applied DNA Clinical Labs (ADCL) in June 2025. The forecasted annual revenue for Applied DNA Sciences, Inc. for the fiscal year ending 2025-09-30 is set at $9 million.

To give you context on the year-to-date performance leading into that forecast, here is a look at the reported total revenues for the first three quarters of fiscal year 2025:

Fiscal Quarter End Date	Total Revenue Amount
December 31, 2024 (Q1 FY2025)	$1.2 million
March 31, 2025 (Q2 FY2025)	$983 thousand
June 30, 2025 (Q3 FY2025)	$304 thousand

Revenue from Therapeutic DNA Production Services (LineaRx segment) is the primary driver now that the company is exclusively focused on synthetic DNA manufacturing. For the second quarter of fiscal 2025, the LineaRx segment revenues showed a significant year-over-year increase of 44% compared to the same period in fiscal 2024. This increase in segment revenue was specifically attributed to two key factors:

• The timing of shipments for a second large-scale DNA manufacturing customer.
• A large shipment delivered to an existing large-scale DNA manufacturing customer.

Sales of LineaDNA™ IVT templates and finished DNA constructs are directly supported by the newly certified GMP Site 1 facility in Stony Brook, New York, which achieved commercial operation certification in January 2025. This facility enables the enzymatic manufacture of Linea DNA™ IVT templates, which are critical for producing mRNA clinical trial materials. The initial projected manufacturing capacity of Site 1 is approximately ten grams per annum, which supports potential annual revenues in the range of $10 million to $30 million, depending on the product mix.

Follow-on orders from existing large-scale DNA manufacturing customers are a confirmed source of revenue within the LineaRx segment. During the second quarter of fiscal 2025, Applied DNA Sciences, Inc. reported receiving specific follow-on orders, which included:

• A quantity of RUO-grade LineaDNA IVT templates to an APAC-based CDMO of mRNA vaccines and therapeutics.
• A quantity of LineaDNA to a U.S.-based CRISPR and mRNA therapeutics developer.
• Continued large-scale manufacturing and delivery of LineaDNA under existing supply agreements with global manufacturers of in vitro diagnostics (IVDs).

Licensing and royalty fees from proprietary LineaRNAP™ technology represent a developing revenue stream. Applied DNA Sciences, Inc. launched industry marketing for LineaRNAP as a standalone product in the third quarter of fiscal 2025, based on data confirming its use in conventional mRNA production workflows to achieve higher mRNA yields and integrity. The company also continues to market LineaRNAP as a component of its integrated LineaIVT solution.